

RUNX3 Polyclonal Antibody

Catalog # AP72377

Product Information

Application WB Primary Accession Q13761

Reactivity Human, Mouse

HostRabbitClonalityPolyclonalCalculated MW44356

Additional Information

Gene ID 864

Other Names RUNX3; AML2; CBFA3; PEBP2A3; Runt-related transcription factor 3; Acute

myeloid leukemia 2 protein; Core-binding factor subunit alpha-3; CBF-alpha-3; Oncogene AML-2; Polyomavirus enhancer-binding protein 2 alpha C subunit;

PEA2-alpha C; PEB

Dilution WB~~Western Blot: 1/500 - 1/2000. ELISA: 1/40000. Not yet tested in other

applications.

Format Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium

azide.

Storage Conditions -20°C

Protein Information

Name RUNX3

Synonyms AML2, CBFA3, PEBP2A3

Function Forms the heterodimeric complex core-binding factor (CBF) with CBFB.

RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'- TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The

heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (By similarity). May be involved in the control of cellular proliferation and/or differentiation. In association with

ZFHX3, up- regulates CDKN1A promoter activity following TGF-beta

stimulation (PubMed: <u>20599712</u>). CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding

sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Necessary for the development and survival of sensory neurons expressing parvalbumin (By similarity).

Cellular Location Nucleus {ECO:0000255 | PROSITE-ProRule:PRU00399,

ECO:0000269 | PubMed:20100835, ECO:0000269 | PubMed:20599712 }. Cytoplasm. Note=The tyrosine phosphorylated form localizes to the cytoplasm. Translocates from the cytoplasm to the nucleus following TGF-beta


stimulation

Tissue Location Expressed in gastric cancer tissues (at protein level).

Background

Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (By similarity). May be involved in the control of cellular proliferation and/or differentiation. In association with ZFHX3, upregulates CDKN1A promoter activity following TGF-beta stimulation (PubMed:20599712). CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity).

Images



Western Blot analysis of various cells using RUNX3 Polyclonal Antibody diluted at 1:500 cells nucleus extracted by Minute TM Cytoplasmic and Nuclear Fractionation kit (SC-003, Inventbiotech, MN, USA).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.